ASAM Pocket Guidelines and Patient Guide

Stimulant Use Disorder

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1519511

Contents of this Issue

Navigation

Page 8 of 29

9 Table 1. Medication Dosing in Clinical Trials a Drug Dose SUD Modafinil 100–400 mg/day (or 200 mg BID) Cocaine Modafinil 400 mg/day Cocaine, ATS Topiramate + MAS-ER Topiramate max 100–150 mg BID + MAS-ER max 60 mg/day Cocaine MAS-ER 60–80 mg/day Cocaine Dextroamphetamine (d-AMP-SR) 20–60 mg/day Cocaine Methylphenidate ER 54–72 mg/day ATS Methylphenidate SR 20–40 mg BID Cocaine Methylphenidate SR 54 mg/day ATS Methylphenidate short acting 20–60 mg/day (Mean 37.6 mg/day b ) ATS Methylphenidate 5–10 mg/day ATS a is appendix presents a summary of dosing strategies used in the clinical trials reviewed, but is not intended as a dosing guide. See full text guideline appendices for references. Available at: https://www.asam.org/ quality-care/clinical-guidelines/stimulant-use-disorders. b Patients self-titrated within this dose range. ATS, amphetamine-type stimulant; BID, two times per day; d-AMP, dextroamphetamine; d-AMP-SR, sustained-release dextroamphetamine; ER, extended release; LDX, lisdexamfetamine; MAS-ER, extended-release mixed amphetamine salts; SR, sustained release

Articles in this issue

Links on this page

view archives of ASAM Pocket Guidelines and Patient Guide - Stimulant Use Disorder